人用药品委员会(CHMP)2026年11月9日至12日会议要点
正文 · 中文译文
欧洲药品管理局(EMA)人用药品委员会(CHMP)在其2026年11月会议上推荐了七种药品供批准。 该委员会建议授予Aumseqa(aumolertinib,奥莫替尼)上市许可,用于治疗非小细胞肺癌。 CHMP建议授予Baxfendy(baxdrostat,巴曲司他)上市许可,用于治疗控制不充分的高血压。 Zybrivo(sintilimab,信迪利单抗)获得CHMP的正面意见,用于治疗成人非鳞状非小细胞肺癌。 该委员会对两种生物类似药通过了正面意见,即Garzulys(insulin aspart,门冬胰岛素)和Donrafylix(insulin aspart,门冬胰岛素),用于治疗成人、青少年及1岁及以上儿童的糖尿病。 两种仿制药获得正面意见: Fondaparinux sodium Evumed(fondaparinux sodium,磺达肝癸钠),用于预防成人静脉血栓栓塞事件,以及治疗深静脉血栓形成、肺栓塞、不稳定型心绞痛和心肌梗死。 Ruxolitinib Krka(ruxolitinib,芦可替尼),用于治疗成人骨髓纤维化和真性红细胞增多症,以及治疗成人和儿童移植物抗宿主病。 关于11种药品治疗适应症扩展的建议 CHMP建议将Gazyvaro(obinutuzumab)的适应症扩展至治疗中重度活动性系统性红斑狼疮成人患者。系统性红斑狼疮是一种主要影响女性的自身免疫性疾病,当免疫系统攻击机体自身组织时发病,引起可损伤器官的炎症。Gazyvaro可满足标准治疗未能充分控制病情的患者的需求。它可降低疾病活动度,同时使患者能够减少糖皮质激素的使用及相关的副作用风险。更多详情请见下方网格中的新闻公告。 委员会还通过了一项肯定意见,将Isturisa(osilodrostat)的治疗适应症扩展至包括治疗6岁及以上青少年和儿童的内源性库欣综合征。库欣综合征是一种罕见疾病,其特征为肾上腺(位于肾脏上方的两个腺体)产生过量激素皮质醇。 委员会建议对另外九种已在欧盟(EU)获批的药品扩展适应症:Bexsero、Cosentyx、Dovato、Enflonsia、Steglatro、Sunlenca、Talzenna、Tivicay、Welireg。 对拟在欧盟以外使用的药品的肯定意见 CHMP建议为达匹韦林阴道环(达匹韦林)增加一种新规格(100mg),用于降低16岁及以上女性通过阴道性交感染1型人类免疫缺陷病毒(HIV-1)的风险。新规格使该环可每三个月更换一次,而非每月更换一次。 该药物是根据名为“EU-Medicines for all(EU-M4All)”的监管程序进行评估的,该程序使EMA能够支持全球监管能力建设,并为欧盟以外的公共卫生保护和促进作出贡献。来自世界卫生组织以及肯尼亚、南非和赞比亚国家监管机构的专家也参与了评估。 在对初始意见进行重新审查后,委员会确认了其拒绝两种药物上市许可的建议: KemSu(舒芬太尼/氯胺酮),拟用于治疗儿童和青少年的急性疼痛。 Meplyffa(阿利莫克洛姆枸橼酸盐),拟用于治疗尼曼-匹克病C型——一种罕见、遗传性、进行性神经退行性疾病——用于两岁及以上患者,与米格鲁司特联合使用。 更多信息,请参见下方表格中的问答文件。 两种药物的初始上市许可申请已被撤回: Amlypave(anselamimab),用于治疗严重影响心脏的kappa轻链淀粉样变性。Kappa轻链淀粉样变性是一种疾病,其中蛋白质(kappa轻链)形成称为淀粉样物质的团块,在组织和器官(如心脏)中积聚,使其无法正常运作。 Qezzaqar(catequentinib),一种用于治疗两种软组织肉瘤的抗癌药物,软组织肉瘤是一种影响身体柔软支撑组织的癌症。 关于撤回这两项申请的问答文件可在下表中查阅。 CHMP已通过一份关于Mounjaro(tirzepatide)对口服避孕药可靠性潜在影响的直接医疗专业人员沟通文件(DHPC)。该DHPC提醒医疗专业人员,对于可能怀孕且正在使用Mounjaro的女性,建议采取避孕措施。文件还指出,关于tirzepatide对肥胖、超重或2型糖尿病女性口服避孕药药代动力学和疗效影响的信息有限。目前建议使用口服避孕药的女性采取以下措施之一: 在开始使用tirzepatide后4周内以及每次剂量增加后4周内,加用屏障避孕方法,或; Mounjaro是一种与饮食和体育锻炼联合使用的药物,用于治疗血糖控制不理想的成人2型糖尿病患者。它也与饮食和体育锻炼联合使用,帮助肥胖(BMI为30 kg/m2或以上)或超重(BMI在27至30 kg/m2之间)且伴有体重相关健康问题的人群减轻体重并保持体重得到控制。 根据欧洲委员会的决定,DHPC将由上市许可持有人向医疗保健专业人员传播,并在EMA网站和欧盟成员国的国家登记册上发布。 2026年11月CHMP会议议程已发布。会议纪要将在未来几周内发布。 2026年11月CHMP会议的关键数据在下图中展示。 2026年11月统计数据——CHMP意见和撤回申请的月度及累计数据: 7项新药正面意见:3项新的非孤儿药、2项生物类似药和2项仿制药/混合药。2026年总计:79 0项新药负面意见。2026年总计:8 11项治疗适应症扩展的正面意见。2026年总计:108 2项新药申请撤回。2026年总计:12 成人非鳞状非小细胞肺癌的治疗 关于新生物类似药的正面推荐 静脉血栓栓塞事件(VTE)的预防、深静脉血栓形成(DVT)的治疗、肺栓塞的治疗、不稳定型心绞痛和心肌梗死的治疗(成人) 成人骨髓纤维化(MF)和真性红细胞增多症(PV)的治疗,以及成人和儿童移植物抗宿主病(GvHD)的治疗 对治疗适应症扩展的肯定性建议 B群脑膜炎球菌疫苗(rDNA,组分,吸附) EMA建议将Gazyvaro的用途扩展至系统性红斑狼疮 1岁至18岁以下儿童急性疼痛的治疗 C型尼曼-匹克病的治疗,这是一种罕见的遗传性进行性神经退行性疾病,用于两岁及以上患者,与米格鲁司特联合使用 初始上市许可申请的撤回 成人kappa轻链淀粉样变性患者的治疗 对拟在欧盟以外使用药品的肯定性意见 请注意,与本页面相关的文件并非全部同时发布。本页面将在新文件可用时立即更新。因此,请用户定期查看本页面。 人用药品委员会(CHMP):2026年11月9-12日 人用药品委员会(CHMP) 电话:+31 (0)88 781 8427 电子邮箱:press@ema.europa.eu
正文 · 英文原文
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its November 2026 meeting. The committee recommended granting a marketing authorisation for Aumseqa (aumolertinib), for the treatment of non-small cell lung cancer. The CHMP recommended granting a marketing authorisation for Baxfendy (baxdrostat), for the treatment of insufficiently controlled hypertension. Zybrivo (sintilimab) received a positive opinion from the CHMP for the treatment of non-squamous non-small cell lung cancer in adults. The committee adopted positive opinions for two biosimilar medicines, Garzulys (insulin aspart) and Donrafylix (insulin aspart), for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. Two generic medicines received a positive opinion: Fondaparinux sodium Evumed (fondaparinux sodium), for the prevention of venous thromboembolic events, and the treatment of deep vein thrombosis, pulmonary embolism, unstable angina and myocardial infarction in adults. Ruxolitinib Krka (ruxolitinib), for the treatment of myelofibrosis and polycythaemia vera in adults, and treatment of Graft-versus-host disease in adults and children. Recommendations on extensions of therapeutic indication for 11 medicines The CHMP recommended extending the use of Gazyvaro (obinutuzumab) to treat adults with moderate-to-severe active systemic lupus erythematosus, an autoimmune disease predominantly affecting women that occurs when the immune system attacks the body’s own tissues, causing inflammation that can damage organs. Gazyvaro addresses needs of patients whose disease is not adequately controlled by standard treatment. It reduces disease activity while allowing patients to reduce their corticosteroid use and the associated risk of side effects. See more details in the news announcement in the grid below. The committee also adopted a positive opinion to extend the therapeutic indication of Isturisa (osilodrostat), to include the treatment of endogenous Cushing’s syndrome in adolescents and children aged 6 years and older. Cushing syndrome is a rare disease characterised by an excess production of the hormone cortisol by the adrenal glands, two glands situated above the kidneys. The committee recommended extensions of indication for another nine medicines that are already authorised in the European Union (EU): Bexsero , Cosentyx , Dovato , Enflonsia , Steglatro , Sunlenca , Talzenna , Tivicay , Welireg . Positive opinions for medicines intended for use outside the EU The CHMP recommended a new strength (100mg) for Dapivirine Vaginal Ring (dapivirine), used to reduce the risk of women 16 years and older getting infected with human immunodeficiency virus type 1 (HIV-1) through vaginal intercourse. The new strength allows the ring to be replaced every three months, instead of every month. This medicine was assessed under a regulatory procedure known as EU-Medicines for all (EU-M4All) that enables EMA to support global regulatory capacity building and contribute to the protection and promotion of public health beyond the EU. Experts from the World Health Organization and national regulators from Kenia, South Africa and Zambia also participated in the assessment. Following a re-examination of its initial opinion, the committee has confirmed its recommendation to refuse a marketing authorisation for two medicines: KemSu (sufentanil / ketamine), intended for the treatment of acute pain in children and adolescents. Meplyffa (arimoclomol citrate), intended for treatment of Niemann-Pick disease type C, a rare, inherited, progressive neurodegenerative disorder, in patients aged two years and older in combination with miglustat. For more information, see the question-and-answer documents in the grid below. Applications for initial marketing authorisation for two medicines were withdrawn: Amlypave (anselamimab), for the treatment of kappa light chain amyloidosis that seriously affects the heart. Kappa light chain amyloidosis is a disease in which proteins (kappa light chains) form clumps called amyloids that build up in tissues and organs, such as the heart, and prevent them from working properly. Qezzaqar (catequentinib), a cancer medicine for two types of soft tissue sarcoma, a type of cancer that affects the soft, supportive tissues of the body. Question-and-answer documents on the withdrawal of these two applications are available in the grid below. The CHMP has adopted a direct healthcare professional communication (DHPC) about the potential effect of Mounjaro (tirzepatide) on the reliability of oral contraceptives. The DHPC reminds healthcare professionals that contraception is recommended for women who can become pregnant and are using Mounjaro. It also states that limited information is available on the effect of tirzepatide on the pharmacokinetics and efficacy of oral contraceptives in women with obesity, overweight or type 2 diabetes mellitus. Women using an oral contraceptive are now advised to either: add a barrier method of contraception for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase, or; Mounjaro is a medicine used together with diet and physical activity to treat adults with type 2 diabetes which is not satisfactorily controlled. It is also used together with diet and physical activity to help people with obesity (BMI of 30 kg/m2 or more) or who are overweight (BMI between 27 and 30 kg/m2) and who have weight-related health problems lose weight and keep their weight under control. Following a decision by the European Commission, the DHPC will be disseminated to healthcare professionals by the marketing authorisation holder and published on the EMA website and in national registers in EU Member States. The agenda of the November 2026 CHMP meeting is published. Minutes of the meeting will be published in the coming weeks. Key figures from the November 2026 CHMP meeting are represented in the graphic below. November 2026 statistics - monthly and cumulative figures for CHMP opinions and withdrawn applications: 7 positive opinions on new medicines: 3 new non-orphan medicines, 2 biosimilar medicines and 2 generic / hybrid medicines. Total in 2026: 79 0 negative opinions on new medicines. Total in 2026: 8 11 positive opinions on extensions of therapeutic indication. Total in 2026: 108 2 withdrawn applications for new medicine. Total in 2026: 12 Treatment of non-squamous non-small cell lung cancer in adults Positive recommendations on new biosimilar medicines Prevention of venous thromboembolic events (VTE), treatment of deep vein thrombosis (DVT), treatment of pulmonary embolism, treatment of unstable angina and myocardial infarction in adults Treatment of myelofibrosis (MF) and polycythaemia vera (PV) in adults, and treatment of Graft versus host disease (GvHD) in adults and children Positive recommendations on extensions of therapeutic indications meningococcal group b vaccine (rDNA, component, adsorbed) EMA recommends extending Gazyvaro’s use to systemic lupus erythematosus Treatment of acute pain in children aged 1 to less than 18 years Treatment of Niemann-Pick disease type C, a rare, inherited, progressive neurodegenerative disorder, in patients aged two years and older in combination with miglustat Withdrawals of initial marketing authorisation applications Treatment of adult patients with kappa light chain amyloidosis Positive opinions for medicines intended for use outside EU Please note that not all documents associated with this page are published at the same time. This page is updated with new documents as soon as they become available. Therefore, users are asked to check the page regularly. Committee for Medicinal Products for Human Use (CHMP): 9-12 November 2026 Committee for Medicinal Products for Human Use (CHMP) Tel. +31 (0)88 781 8427 E-mail: press@ema.europa.eu